Asset Details
Do you wish to reserve the book?
Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models
Do you wish to request the book?
Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models
2025
Overview
Metastatic prostate cancer is incurable, and new therapeutic targets and drugs are urgently needed. Viral infections are associated with several cancer types, but a link between viruses and prostate oncogenesis has not been established. Only recently, an association between human cytomegalovirus (CMV) seropositivity and increased risk of prostate cancer mortality was demonstrated. Here, we show that CMV infection is common in the normal prostate epithelium and in prostate tumor tissue, with 70–92% of tumors being infected. Additionally, we report that commonly studied prostate cancer cell lines are CMV infected. Loss‐of‐function experiments demonstrate that CMV promotes cell survival, proliferation, and androgen receptor signaling, identifying it as a therapeutic target in castration‐sensitive and castration‐resistant prostate cancer. Several anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models both in vitro and in vivo. We conclude that CMV is common in prostate cancer, promotes core prostate cancer cell programs, and can be inhibited by well‐tolerated drugs. These findings motivate investigation into potential clinical benefits of CMV inhibition in the treatment of prostate cancer. Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation into potential clinical benefits of CMV inhibition in the treatment of prostate cancer.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Animals
/ Antiviral Agents - pharmacology
/ Antiviral Agents - therapeutic use
/ Cell Proliferation - drug effects
/ Cytomegalovirus - drug effects
/ Cytomegalovirus - physiology
/ Cytomegalovirus Infections - complications
/ Cytomegalovirus Infections - drug therapy
/ Cytomegalovirus Infections - virology
/ Ethics
/ Humans
/ Infectious Agents and Cancer
/ Male
/ Mice
/ Prostatic Neoplasms - complications
/ Prostatic Neoplasms - drug therapy
/ Prostatic Neoplasms - pathology
/ Prostatic Neoplasms - virology
/ Receptors, Androgen - metabolism
/ Viruses
